StreetInsider.com News Articles

Contineum Therapeutics (CTNM) PT Raised to $30 at Jones Trading

Wed, 14 Oct 2026 07:07:47 -0400

Jones Trading analyst Debanjana Chatterjee raised the price target on Contineum Therapeutics (NASDAQ: CTNM) to $30.00 (from $24.00) while maintaining a Buy rating.

Baird Downgrades Contineum Therapeutics (CTNM) to Neutral

Tue, 13 Oct 2026 08:43:56 -0400

(Updated - October 13, 2026 8:43 AM EDT)

Baird analyst Joel Beatty downgraded Contineum Therapeutics (NASDAQ: CTNM) from Outperform to Neutral with a price target of $14.00 (from $19.00).

The analyst comments "Downgrading to Neutral on Bristol IPF results. Contineum's hypothesis for greater LPA1R occupancy leading to greater efficacy in IPF took a hit from Bristol's ALOFT-IPF topline, where 60mg BID admilparant achieved significance but 120mg BID only showed numerical benefit. The miss on 120mg when both Bristol and Contineum expect greater efficacy from higher occupancy undermines the mechanism's potential, even if PIPE-791 is a much better molecule. Taken together with Contineum's

Baird Downgrades Contineum Therapeutics (CTNM) to Neutral

Tue, 13 Oct 2026 08:43:56 -0400

(Updated - October 13, 2026 8:43 AM EDT)

Baird analyst Joel Beatty downgraded Contineum Therapeutics (NASDAQ: CTNM) from Outperform to Neutral with a price target of $14.00 (from $19.00).

Contineum Therapeutics stock surges on Bristol Myers trial win

Mon, 12 Oct 2026 07:27:39 -0400

Investing.com -- Contineum Therapeutics (NASDAQ:CTNM) shares rose 27% in pre-market trading Monday following Bristol Myers Squibb’s announcement that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.

The stock was indicated at $16.99 in pre-market trading, up from its Friday close of $13.38. Contineum’s lead asset, PIPE-791, targets the same biological pathway as Bristol Myers’ admilparant.

Both PIPE-791 and admilparant are LPA1 antagonists being developed for idiopathic pulmonary fibrosis. PIPE-791 is currently in a Phase 2 trial. Bristol Myers’ Phase 3 success at the 60 mg dose represents the first

Contineum Therapeutics stock surges on Bristol Myers trial win

Mon, 12 Oct 2026 07:27:39 -0400

The stock was indicated at $16.99 in pre-market trading, up from its Friday close of $13.38. Contineum’s lead asset, PIPE-791, targets the same biological pathway as Bristol Myers’ admilparant.

Form 144 Contineum Therapeutics, Filed by: Lorrain Daniel S.

Thu, 01 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261001/27136279.html

Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)

Wed, 30 Sep 2026 09:58:54 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $28.00 price target on Contineum Therapeutics (NASDAQ: CTNM).

The analyst commented, "CTNM shares traded lower today on the circulation of a protocol amendment for the BMY admilparant trial, the outcome of which is core to the CTNM thesis for PIPE-791. Specifically, the protocol amendment disclosed a single fatal case of multi-organ failure involving hepatic injury, HLH, autoimmune hermolytic anemia and other factors occurred during the admilparant ph3 trial. From our seat though we think this should have little readthrough onto CTNM based on what's known: (1) biologically, it's hard to believe this

Wells Fargo Sees Liver Safety Risk In Bristol Admilparant Trial - Bloomberg

Tue, 29 Sep 2026 16:45:30 -0400

Wells Fargo Sees Liver Safety Risk In Bristol Admilparant Trial - Bloomberg

Tue, 29 Sep 2026 16:45:30 -0400

Wells Fargo Sees Liver Safety Risk In Bristol Admilparant Trial - Bloomberg

Contineum Therapeutics (CTNM) Halted on Volatility, Down 15%

Tue, 29 Sep 2026 15:52:00 -0400

Contineum Therapeutics (NASDAQ: CTNM) Halted on Volatility, Down 15%

Contineum Therapeutics (CTNM) PT Lowered to $17 at Morgan Stanley

Mon, 28 Sep 2026 08:25:44 -0400

Morgan Stanley analyst Jeffrey Hung lowered the price target on Contineum Therapeutics (NASDAQ: CTNM) to $17.00 (from $18.00) while maintaining a Equalweight rating.

Goldman Sachs Assumes Contineum Therapeutics (CTNM) at Early-Stage Biotech

Thu, 24 Sep 2026 05:33:55 -0400

(Updated - September 24, 2026 5:33 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Early-Stage Biotech rating.

The analyst comments "CTNM is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic indications. The clinical pipeline includes wholly-owned lead candidate PIPE-791, a brain-penetrant lysophosphatidic acid 1 receptor (LPAR1) antagonist, which is currently being evaluated in the Ph2 PROPEL-IPF trial for the treatment of idiopathic pulmonary fibrosis (IPF). Following positive exploratory Ph1b results, CTNM may also explore PIPE-791 for the potential treatment of chronic pain."

For an analyst ratings summary and ratings

Goldman Sachs Assumes Contineum Therapeutics (CTNM) at Early-Stage Biotech

Thu, 24 Sep 2026 05:33:55 -0400

(Updated - September 24, 2026 5:33 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Early-Stage Biotech rating.

For an analyst ratings summary and ratings

Form 8-K Contineum Therapeutics, For: Sep 14

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091832.html

Contineum Therapeutics (CTNM) PT Lowered to $21 at RBC Capital

Mon, 21 Sep 2026 08:24:47 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Contineum Therapeutics (NASDAQ: CTNM) to $21.00 (from $23.00) while maintaining a Outperform rating.

Contineum Therapeutics (CTNM) Reiterated at Buy by Stifel as M1R Agonist Fails Ph2 Study

Tue, 15 Sep 2026 06:56:22 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $28.00 price target on Contineum Therapeutics (NASDAQ: CTNM).

The analyst commented, "CTNM announced today that PIPE-307/JNJ-5120/, their selective M1R antagonist, failed its ph2 study in MDD. The study did not meet the primary endpoint, change from baseline in MADRS at Day 5--analyses of the data, including prespecified exploratory endpoints, remain ongoing and results there will be used to inform potential next steps for development. While we've found this program to be an interesting, more under-the-radar catalyst for CTNM with an upside-skew (the prior ISTs assessing scopolamine offered promising support but with significant

Contineum Therapeutics (CTNM) PT Lowered to $19 at Baird

Tue, 15 Sep 2026 05:00:50 -0400

Baird analyst Joel Beatty lowered the price target on Contineum Therapeutics (NASDAQ: CTNM) to $19.00 (from $20.00) while maintaining a Outperform rating.

Form 8-K Contineum Therapeutics, For: Sep 14

Mon, 14 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260914/27058451.html

Contineum drug trial fails to meet primary endpoint for depression

Mon, 14 Sep 2026 16:05:31 -0400

Contineum Therapeutics (NASDAQ: CTNM) announced that its Phase 2 MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307 for the treatment of major depressive disorder (MDD) did not meet its primary efficacy endpoint.

The trial measured improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo. The drug was reported as well-tolerated with no new safety signals identified.

JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement with Contineum. Johnson & Johnson said it continues to evaluate the trial data, including data related to prespecified exploratory endpoints, to assess the totality and clinical

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Mon, 14 Sep 2026 16:05:00 -0400

Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint
Analyses of the data, including prespecified exploratory endpoints, are ongoing

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo. JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.

JNJ-5120/PIPE-307 is being developed by Johnson

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Mon, 14 Sep 2026 16:05:00 -0400

Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint
Analyses of the data, including prespecified exploratory endpoints, are ongoing

JNJ-5120/PIPE-307 is being developed by Johnson

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Tue, 25 Aug 2026 16:05:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Tue, 25 Aug 2026 16:05:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Tue, 25 Aug 2026 16:05:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Tue, 25 Aug 2026 16:05:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies